High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
about
Fifty years of melphalan use in hematopoietic stem cell transplantationSecondary leukaemia and myelodysplasia after autografting for lymphoma: is the transplant to blame?Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation.Autologous hematopoietic stem cell transplantation in lymphoma patients is associated with a decrease in the double strand break repair capacity of peripheral blood lymphocytesDoes autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?Second malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma - characteristics and risk factor analysis.Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients.Long-term safety of granulocyte colony-stimulating factor in normal donors: is it all clear?Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited.Evaluation for the development of 11q23 rearrangements in lymphoma patients treated with a high dose VP-16 and cyclophosphamide salvage regimen.Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma.Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma.[Stem cell transplantation for multiple sclerosis. Hamburg experiences and state of international research].
P2860
Q26824498-64F84431-B9BB-4C3F-BA46-0241E1BBD877Q34244398-734A3898-B85A-4757-B149-D080CB473446Q35849268-4AA04909-4AC6-44E4-9948-7F622C5A9F1FQ36282672-295405EC-C596-4C62-A99E-B1A71091050AQ36672691-13175CCC-C3EC-4211-9786-EA7BF3490C86Q36936841-9797BF83-1D3D-40F1-A223-1630C4F74E92Q37103073-2B7EC30F-4933-4C49-813B-F09F325EA6BDQ37548821-60D67BC0-31BD-443B-AC55-B3C3F71C0455Q37996560-1757711A-B8FC-4D54-BD6C-A20436003B5DQ39576312-0BBACEA5-31F1-44DF-8E87-6632AD38D177Q44509212-A0A7782D-8857-43F8-9120-4D95668D1EC7Q44511397-BA8AEAD1-6B2B-4561-BD98-F4BC022E380EQ48389559-6CBCDBF4-9201-4C48-9931-94EA26B54DF1Q52944830-99C30E95-4AAF-4BF7-B380-E6F9DEED21F0
P2860
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
High-dose BEAM chemotherapy wi ...... sed risk of secondary MDS/AML.
@ast
High-dose BEAM chemotherapy wi ...... sed risk of secondary MDS/AML.
@en
type
label
High-dose BEAM chemotherapy wi ...... sed risk of secondary MDS/AML.
@ast
High-dose BEAM chemotherapy wi ...... sed risk of secondary MDS/AML.
@en
prefLabel
High-dose BEAM chemotherapy wi ...... sed risk of secondary MDS/AML.
@ast
High-dose BEAM chemotherapy wi ...... sed risk of secondary MDS/AML.
@en
P2093
P2860
P356
P1476
High-dose BEAM chemotherapy wi ...... sed risk of secondary MDS/AML.
@en
P2093
Devereux S
Goldstone AH
Harrison CN
MacMillan AK
Milligan D
P2860
P2888
P304
P356
10.1038/SJ.BJC.6690718
P407
P577
1999-10-01T00:00:00Z